Drugs / Rituxumab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT03677141 Comparator | Mar 2019 → Oct 2023 | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT07570823 Comparator | May 2026 → Nov 2027 expected | diffuse large B-cell lymphoma | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituxumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03677141 ↗ |
| Route | Intravenous | “rituxumab via IV” NCT03677141 ↗ |